DM
Therapeutic Areas
Skinvisible Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Invisicare Dermatology Platform | Various Dermatological Conditions (e.g., via licensee) | Phase 2/3 (via licensee) |
| QRX003 (via Quoin Pharmaceuticals) | Netherton Syndrome | Clinical Trials |
| Transdermal Obesity Formulations | Obesity / Glucose Control | Pre-clinical |
| Cannabinoid Delivery (with Ovation Science) | Obesity / Metabolic Health | Research |
Leadership Team at Skinvisible Pharmaceuticals
TH
Terry Howlett
President & Chief Executive Officer
JA
James A. Roszell, PhD
Head, Research & Development